Filtered By:
Drug: Tarceva
This page shows you your search results in order of relevance. This is page number 5.
Order by Relevance | Date
Total 64 results found since Jan 2013.
The combination of osimertinib with Raf inhibitor overcomes osimertinib resistance induced by KRAS amplification in EGFR-mutated lung cancer cells
Exp Cell Res. 2023 Jul 11:113722. doi: 10.1016/j.yexcr.2023.113722. Online ahead of print.ABSTRACTOsimertinib is a third-generation epidermal growth factor receptor (EGFR)1 tyrosine kinase inhibitor (TKI) approved for the treatment of EGFR-positive patients exhibiting a T790 M resistance mutation after treatment with an earlier generation of EGFR TKIs. However, resistance to osimertinib inevitably develops despite its efficacy, and the resistance mechanisms are complex and not fully understood. We established cell lines with acquired resistance to osimertinib from gefitinib- or erlotinib-resistant NSCLC cells using a dose-...
Source: Experimental Cell Research - July 13, 2023 Category: Cytology Authors: Tae-Gul Lee Hye-Min Kang Seo Yun Kim Hye-Ryoun Kim Cheol Hyeon Kim Source Type: research
